New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 19, 2012
07:32 EDTHALO, VPHMViroPharma, Halozyme announce initiation of Phase 2b dose to evaluate Cinryze
ViroPharma (VPHM) and Halozyme (HALO) announced that ViroPharma has initiated its Phase 2b double blind, multicenter, dose ranging study to evaluate the safety and efficacy of subcutaneous administration of Cinryze in combination with Halozyme's Enhanze technology in adolescents and adults with hereditary angioedema for prevention of HAE attacks. This double blind, cross-over, dose ranging study will be conducted in approximately 40 adolescent and adult subjects in the U.S. and Europe. The primary efficacy endpoint is the normalized number of angioedema attacks recorded during each treatment period. In addition, several secondary endpoints will be assessed, including attack severity, quality of life parameters using a novel angioedema tool, and number of angioedema attacks requiring acute treatment.
News For VPHM;HALO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 20, 2015
08:24 EDTHALOHalozyme PEGPH20 data supports ongoing work
Subscribe for More Information
07:57 EDTHALOHalozyme an underappreciated story with catalysts, says UBS
Subscribe for More Information
April 17, 2015
07:14 EDTHALOHalozyme management to meet with UBS
Subscribe for More Information
April 16, 2015
07:10 EDTHALOHalozyme management to meet with UBS
Subscribe for More Information
April 14, 2015
07:10 EDTHALOHalozyme management to meet with UBS
Subscribe for More Information
April 13, 2015
09:05 EDTHALOHalozyme appoints Harry Leonhardt as Chief Compliance Officer
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use